This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

Early Bird pricing expires in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
3 days in-person. 3 days virtually.
March 20–22, 2023 | Basel, SwitzerlandMarch 28–30, 2023 | Digital

ImStar Therapeutics

Profile

Canada

ImStar Therapeutics is a private biotechnology company developing new therapeutic approaches to treat patients with neurodegenerative diseases. The lead drug candidate, IMS-088, is a disease-modifying novel compound for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) that acts via rescue of TAR DNA-binding protein 43 (TDP-43) proteinopathy associated with these devastating neurodegenerative diseases. ImStar is also developing mAb therapeutics directed at TDP-43.

Presenter: Daniel Wattier, CEO, ImStar Therapeutics